Physician profile
Murray G Honick
NPI 1932183357
$125,235.83
in general payments reported to CMS, 2019-2025
28 companies · $91.89 in 2025
The $91.89 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26K · 2020: $8,487 · 2021: $35K · 2022: $29K · 2023: $23K · 2024: $4,612 · 2025: $91.89.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $19K · Travel and Lodging: $3,327 · Food and Beverage: $3,214 · Honoraria: $2,275.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $18,750.00 |
| Travel and Lodging | $3,327.04 |
| Food and Beverage | $3,213.68 |
| Honoraria | $2,275.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $85,028.40 | 2021-2024 | Qelbree, Qelbree |
| Ironshore Pharmaceuticals INC. | $33,300.06 | 2019-2024 | Jornay Pm |
| Abbvie INC. | $1,034.88 | 2021-2025 | |
| Sunovion Pharmaceuticals INC. | $787.66 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $585.28 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Corium, LLC | $569.95 | 2022-2024 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $489.55 | 2019-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $447.89 | 2019-2024 | Invega Trinza, Invega Sustenna, Spravato |
| Lundbeck LLC | $441.28 | 2019-2025 | Rexulti, Vyepti |
| Teva Pharmaceuticals USA, INC. | $416.83 | 2019-2024 | Uzedy |
| Adlon Therapeutics L.P. | $305.54 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $283.90 | 2019-2024 | Ingrezza |
| Alkermes, INC. | $210.83 | 2019-2024 | Lybalvi |
| Axsome Therapeutics, INC. | $196.95 | 2023-2024 | Auvelity, Sunosi |
| Tris Pharma INC | $189.22 | 2019-2025 | Dyanavel Xr, Onyda Xr |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $173.15 | 2019-2024 | Hetlioz, Fanapt |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $137.83 | 2021-2024 | Caplyta |
| Bausch Health US, LLC | $115.15 | 2019-2022 | |
| Avanir Pharmaceuticals, INC. | $105.96 | 2019 | |
| Jazz Pharmaceuticals INC. | $87.21 | 2019-2020 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $85.15 | 2022 | |
| Allergan, INC. | $55.85 | 2019-2020 | |
| Shire North American Group INC | $52.76 | 2019 | |
| Indivior INC. | $52.53 | 2019-2021 | |
| Neos Therapeutics, LP | $44.16 | 2020-2024 | Adzenys Xr-Odt |
| Idorsia Pharmaceuticals US INC | $13.79 | 2022 | |
| Arbor Pharmaceuticals, INC. | $12.66 | 2019 | |
| Eisai INC. | $11.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Murray Honick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.